Shin Nippon Biomedical Laboratories (FRA:YB3) Total Liabilities : €261.9 Mil (As of Dec. 2023)

View and export this data going back to 2004. Start your Free Trial

What is Shin Nippon Biomedical Laboratories Total Liabilities?

Shin Nippon Biomedical Laboratories's Total Liabilities for the quarter that ended in Dec. 2023 was €261.9 Mil.

Shin Nippon Biomedical Laboratories's quarterly Total Liabilities declined from Jun. 2023 (€234.26 Mil) to Sep. 2023 (€233.46 Mil) but then increased from Sep. 2023 (€233.46 Mil) to Dec. 2023 (€261.88 Mil).

Shin Nippon Biomedical Laboratories's annual Total Liabilities increased from Mar. 2022 (€150.01 Mil) to Mar. 2023 (€215.80 Mil) and increased from Mar. 2023 (€215.80 Mil) to Mar. 2024 (€258.78 Mil).

Shin Nippon Biomedical Laboratories Total Liabilities Historical Data

The historical data trend for Shin Nippon Biomedical Laboratories's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shin Nippon Biomedical Laboratories Total Liabilities Chart

Shin Nippon Biomedical Laboratories Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Total Liabilities

Get a 7-Day Free Trial

190.14

163.32

150.01

215.80

258.78

Shin Nippon Biomedical Laboratories Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Liabilities	Get a 7-Day Free Trial															215.80	234.26	233.46	261.88	258.78

Shin Nippon Biomedical Laboratories Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Shin Nippon Biomedical Laboratories's Total Liabilities for the fiscal year that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	144.725	+	(112.749	+	1.308
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	258.8

Total Liabilities	=	Total Assets (A: Mar. 2024 )	-	Total Equity (A: Mar. 2024 )
	=	468.554	-	209.772
	=	258.8

Shin Nippon Biomedical Laboratories's Total Liabilities for the quarter that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	142.421	+	(118.994	+	0.465
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	261.9

Total Liabilities	=	Total Assets (Q: Dec. 2023 )	-	Total Equity (Q: Dec. 2023 )
	=	454.557	-	192.677
	=	261.9

Shin Nippon Biomedical Laboratories Total Liabilities Related Terms

Thank you for viewing the detailed overview of Shin Nippon Biomedical Laboratories's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Shin Nippon Biomedical Laboratories (FRA:YB3) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Shin Nippon Biomedical Laboratories Ltd (FRA:YB3) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

2395:Japan

Address

8-1 Akashi-cho, Tokyo, JPN

Website

http://www.snbl.co.jp

Shin Nippon Biomedical Laboratories Ltd provides pre-clinical testing services in the pharmaceutical industry in Japan. The company provides a range of services such as pre-clinical and analysis studies, contracted clinical trials, SMO, CRO, translational research and cancer treatment.

Shin Nippon Biomedical Laboratories (FRA:YB3) Headlines

No Headlines